Yahoo Finance

Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025

MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) will present data ...
Nasdaq

Arvinas Announces Late-Breaking Oral Presentation of Phase 3 VERITAC-2 Trial Results for Vepdegestrant at ASCO 2025

Arvinas will present Phase 3 VERITAC-2 trial results for vepdegestrant at ASCO 2025, evaluating its effectiveness in breast cancer treatment. Arvinas, Inc. announced that it will present the detailed ...
Nasdaq

Affimed Announces Oral Presentation of Phase 1/2 Data from AFM13 in Combination with Allogeneic NK Cells at the 2023 ASH Annual Meeting

MANNHEIM, Germany, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ...
Morningstar

Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting

The presentation will be available on Nektar's website at http://www.nektar.com under Scientific Publications, following the formal presentation. The ongoing global ...
Investing

MindMed August 2025 presentation slides: Phase 3 trials advance with $238M cash runway

Mind Medicine Inc (NASDAQ:MNMD) released its August 2025 corporate presentation on July 31, highlighting the company’s progress in developing novel treatments for brain health disorders. The ...
Seeking Alpha

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

WATERTOWN, Mass., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (LYRA) (Nasdaq: LYRA), (“Lyra” or the “Company”), a late clinical-stage ...